[1]方健文,袁晴,邵毅.人源性肿瘤异种移植模型在眼科的应用进展[J].眼科新进展,2019,39(7):695-697.[doi:10.13389/j.cnki.rao.2019.0160]
 FANG Jian-Wen,YUAN Qing,SHAO Yi.Application progress of patient-derived xenograft model(PDX) in ophthalmology[J].Recent Advances in Ophthalmology,2019,39(7):695-697.[doi:10.13389/j.cnki.rao.2019.0160]
点击复制

人源性肿瘤异种移植模型在眼科的应用进展/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年7期
页码:
695-697
栏目:
文献综述
出版日期:
2019-07-05

文章信息/Info

Title:
Application progress of patient-derived xenograft model(PDX) in ophthalmology
作者:
方健文袁晴邵毅
330006 江西省南昌市,南昌大学第一附属医院眼科
Author(s):
FANG Jian-WenYUAN QingSHAO Yi
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
关键词:
人源性肿瘤异种移植模型视网膜母细胞瘤葡萄膜黑色素瘤脉络膜黑色素瘤结膜黑色素瘤
Keywords:
patient-derived xenograft modelretinoblastomauveal melanomachoroidal melanomamelanoma of conjunctiva
分类号:
R77
DOI:
10.13389/j.cnki.rao.2019.0160
文献标志码:
A
摘要:
人源性肿瘤异种移植模型为肿瘤发生机制的研究、肿瘤药物的筛选和癌症治疗方案的评估提供了良好的临床前试验模型。近年来,人源性肿瘤异种移植模型的建立和应用在肿瘤领域的发展不断进步,在对癌症的研究中发挥重要作用。本文主要介绍人源性肿瘤异种移植模型在眼科肿瘤领域的应用进展。
Abstract:
Patient-derived xenograft model provides a good preclinical trial model for the study of tumor mechanism,screening of tumor drugs and evaluation of cancer treatment.In recent years,the establishment of patient-derived xenograft model and its application in the field of cancer have been developing continuously and play an important role in the research of cancer.This paper mainly introduces the application of patient-derived xenograft model in the field of ophthalmic oncology.

参考文献/References:

[1] HIDALGO M,AMANT F,BIANKIN A V,BUDINSK E,BYRNE A T,CALDAS C,et al.Patient-derived xenograft models:an emerging platform for translational cancer research[J].Cancer Discov,2014,4(9):998-1013.
[2] CASSIDY J W,CALDAS C,BRUNA A.Maintaining tumour heterogeneity in patient-derived tumour xenografts[J].Cancer Res,2015,75(15):2963-2968.
[3] SIA D,MOEINI A,LABGAA I,VILLANUEVA A.The future of patient-derived tumor xenografts in cancer treatment[J].Pharmacogenomics,2015,16(14):1671-1683.
[4] LI K J,HUANG H,GAO R.Research progress of patient-derived xenografts in precision cancer medicine[J].Chin J Comp Med,2017,27(1):91-98.
李克娟,黄昊,高苒.人源肿瘤异种移植模型在精准肿瘤医学中的研究进展[J].中国比较医学杂志,2017,27(1):91-98.
[5] FABIAN I D,ONADIM Z,KARAA E,DUNCAN C,CHOWDHURY T,SCHEIMBERG I,et al.The management of retinoblastoma[J].Oncogene,2018,37(12):1551-1560.
[6] BHAVNA C,GAUTAM L,SUSHMITA P.Recent advances in management of retinoblastoma:A review[J].World J Ophthalmol,2015,5(1):31-35.
[7] CASSOUX N,THULEAU A,ASSAYAG F,AERTS I,DECAUDIN D.Establishment of an orthotopic xenograft mice model of retinoblastoma suitable for preclinical testing[J].Ocul Oncol Pathol,2015,1(3):200-206.
[8] AERTS I,LEURAUD P,BLAIS J,POULIQUEN AL,MAILLARD P,HOUDAYER C,et al.In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma[J].Photodiagnosis Photodyn Ther,2010,7(4):275-283.
[9] ASSAYAG F,NICOLAS A,VACHER S,DEHAINAULT C,BIECHE I,MESEURE D,et al.Combination of carboplatin and bevacizumab is an efficient therapeutic approach in retinoblastoma patient-derived xenografts[J].Invest Ophthalmol Vis Sci,2016,57(11):4916-4926.
[10] LEMAITRE S,POYER F,MARCO S,FRNEAUX P,DOZ F,AERTS I,et al.Looking for the most suitable orthotopic retinoblastoma mouse model in order to characterize the tumoral development[J].Invest Ophthalmol Vis Sci,2017,58(7):3055-3064.
[11] SPAGNOLO F,CALTABIANO G,QUEIROLO P.Uveal melanoma[J].Cancer Treatment Reviews,2012,38(5):549-553.
[12] CARITA G,DECAUDIN D.Uveal melanoma patient-derived xenografts[J].Ocul Oncol Pathol,2015,1(3):161-169.
[13] NMATI F,SASTRE-GARAU X,LAURENT C,COUTURIER J,MARIANI P,DESJARDINS L,et al.Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors[J].Clin Cancer Res,2010,16(8):2352-2362.
[14] LAURENT C,GENTIEN D,PIPERNO-NEUMANN S,NMATI F,NICOLAS A,TESSON B,et al.Patient-derived xenografts recapitulate molecular features of human uveal melanomas[J].Mol Oncol,2013,7(3):625-636.
[15] NMATI F,MONTRION C D,LANG G,KRAUS-BERTHIER L,CARITA G,SASTRE-GARAU X,et al.Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived Xenografts[J].PLoS One,2014,9(1):e80836.
[16] PAL B P,GARGE S,KHETAN V.Choroidal melanoma:a short review with an Indian perspective[J].Oman J Ophthalmol,2017,10(3):135-144.
[17] LEMAITRE S,NEMATI F,THULEAU A,LABIOD D,RODRIGUES M,PLATER L D,et al.Preclinical scheduling for metastatic ocular melanoma treatment by using a xenograft model approach[J].Acta Ophthalmol,2014,92(s253):0.
[18] VORA G K,DEMIRCI H,MARR B,MRUTHYUNJAYA P.Advances in the management of conjunctival melanoma[J].Sur Ophthalmol,2017,62(1):26-42.

相似文献/References:

[1]刘瑾 朱豫.视网膜母细胞瘤的治疗进展[J].眼科新进展,2013,33(1):000.
[2]常海敏 杨磊 千新来.Calphostin C对人视网膜母细胞瘤细胞增殖的抑制作用[J].眼科新进展,2013,33(9):000.
[3]崔平 南娜 康洁 李军会 申景然.白藜芦醇对人视网膜母细胞瘤细胞侵袭能力的影响及机制研究[J].眼科新进展,2012,32(1):000.
[4]宋念艺 陈绪涛 张娴.B超、CT及MRI检查在视网膜母细胞瘤诊断中的价值[J].眼科新进展,2012,32(10):000.
[5]张千帆 刘瑞敏 穆红梅 郭洋 申飞 刘莹.白藜芦醇对视网膜母细胞瘤Y79细胞增殖的影响及其机制[J].眼科新进展,2012,32(11):000.
[6]兰兰 惠延年 曾光伟.微小RNA与磷酸化胞外信号调节激酶在视网膜母细胞瘤中的表达及其相关性分析[J].眼科新进展,2013,33(6):000.
[7]覃冬菊,唐罗生,游庆华,等.HSP27、增殖细胞核抗原在视网膜母细胞瘤中的表达[J].眼科新进展,2010,30(5):000.
[8]蒋永强 吴晓梅 连金贤.视网膜母细胞瘤术后23 a未复发1例[J].眼科新进展,2009,29(1):000.
[9]陈雪 李海平 张培 曹安民. 小胶质细胞在视网膜母细胞瘤中的活化及分布研究[J].眼科新进展,2014,34(1):029.
[10]孙燕 张煦 王登廷 祝杰 郑吉琦. Livin、PTEN及MMP-9在视网膜母细胞瘤中的表达及相关性研究[J].眼科新进展,2014,34(2):135.

备注/Memo

备注/Memo:
国家自然科学基金资助(编号:81660158、81460092、81400372);江西省自然科学基金重大项目(编号:2016ACB21017);江西省青年科学基金(编号:20151BAB215016、20161BAB215198);江西省重点研发项目(编号:20151BBG70223、20181BBG70004);江西省教育厅重点项目(编号:GJJ160020);江西省学位与研究生教育教学改革研究项目(编号:JXYJG-2018-013);江西省基层卫生适宜技术“星火推广计划”项目(编号:20088003);江西省卫计委科技计划面上项目(编号:20175116);江西省卫计委中医药科技计划项目(编号:20150823)
更新日期/Last Update: 2019-07-01